Picture loading failed.

Anti-CD22 therapeutic antibody (Pre-made Pinatuzumab biosimilar,Whole mAb ADC) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Pinatuzumab vedotin (DCDT2980S, FCU2703) is an anti-CD22 antibody-drug conjugate (ADC) developed by Genentech/ Hoffmann-La Roche for the treatment of diffuse large B-cell lymphoma (DLBCL). ... Pinatuzumab vedotin has proved its efficacy in inducing a complete tumor regression in xenograft lymphoma models.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-444-1mg 1mg 3090
GMP-Bios-ab-444-10mg 10mg 21890
GMP-Bios-ab-444-100mg 100mg 148000
GMP-Bios-ab-444-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-CD22 therapeutic antibody (Pre-made Pinatuzumab biosimilar,Whole mAb ADC)
INN Name Pinatuzumab
TargetCD22
FormatWhole mAb ADC
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI Structure6and:HL
95-98% SI StructureNone
Year Proposed2012
Year Recommended2013
CompaniesGenentech
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedChronic lymphocytic leukaemia;Diffuse large B cell lymphoma;Non-Hodgkin's lymphoma
Development Techna